98 related articles for article (PubMed ID: 25853815)
1. Lonafarnib is a potential inhibitor for neovascularization.
Sun L; Xie S; Peng G; Wang J; Li Y; Qin J; Zhong D
PLoS One; 2015; 10(4):e0122830. PubMed ID: 25853815
[TBL] [Abstract][Full Text] [Related]
2. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
3. Lonafarnib for cancer and progeria.
Wong NS; Morse MA
Expert Opin Investig Drugs; 2012 Jul; 21(7):1043-55. PubMed ID: 22620979
[TBL] [Abstract][Full Text] [Related]
4. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
Appels NM; Bolijn MJ; van Eijndhoven MA; Stephens TC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2011 Jan; 67(1):137-45. PubMed ID: 20229082
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Appels NM; van Maanen MJ; Rosing H; Schellens JH; Beijnen JH
Rapid Commun Mass Spectrom; 2005; 19(15):2187-92. PubMed ID: 15996016
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
9. Identification of a cytoplasmic linker protein as a potential target for neovascularization.
Xie S; Dong B; Sun X; Tala ; He X; Zhou J; Liu M; Li D
Atherosclerosis; 2014 Apr; 233(2):403-409. PubMed ID: 24530770
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
11. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.
Wang EJ; Johnson WW
Chemotherapy; 2003 Dec; 49(6):303-8. PubMed ID: 14671431
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.
Bot I; Jukema JW; Lankhuizen IM; van Berkel TJ; Biessen EA
Atherosclerosis; 2011 Feb; 214(2):295-300. PubMed ID: 21130458
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice.
Sun GB; Qin M; Ye JX; Pan RL; Meng XB; Wang M; Luo Y; Li ZY; Wang HW; Sun XB
Toxicol Appl Pharmacol; 2013 Aug; 271(1):114-26. PubMed ID: 23639522
[TBL] [Abstract][Full Text] [Related]
14. An important role of matrix metalloproteinase-8 in angiogenesis in vitro and in vivo.
Fang C; Wen G; Zhang L; Lin L; Moore A; Wu S; Ye S; Xiao Q
Cardiovasc Res; 2013 Jul; 99(1):146-55. PubMed ID: 23512982
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.
Wang J; Lian Y; Gu Y; Wang H; Gu L; Huang Y; Zhou L; Huang Y
Oncotarget; 2017 Dec; 8(62):105047-105060. PubMed ID: 29285232
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J
Cancer; 2006 Jan; 106(2):346-52. PubMed ID: 16342165
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
[TBL] [Abstract][Full Text] [Related]
18. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Adjei AA; Erlichman C; Davis JN; Cutler DL; Sloan JA; Marks RS; Hanson LJ; Svingen PA; Atherton P; Bishop WR; Kirschmeier P; Kaufmann SH
Cancer Res; 2000 Apr; 60(7):1871-7. PubMed ID: 10766174
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
